Coya Therapeutics, Inc. (NASDAQ:COYA) Sees Large Increase in Short Interest

Coya Therapeutics, Inc. (NASDAQ:COYA) was the recipient of a significant growth in short interest in the month of December. As of December 31st, there was short interest totalling 209,200 shares, a growth of 10.2% from the December 15th total of 189,800 shares. Based on an average daily volume of 92,500 shares, the days-to-cover ratio is currently 2.3 days. Approximately 1.4% of the shares of the company are short sold.

Analysts Set New Price Targets

Several brokerages have recently commented on COYA. Chardan Capital reissued a “buy” rating and set a $14.00 price objective on shares of Coya Therapeutics in a report on Thursday, November 7th. D. Boral Capital reaffirmed a “buy” rating and set a $15.00 price objective on shares of Coya Therapeutics in a report on Wednesday, December 18th. Finally, HC Wainwright reissued a “buy” rating and issued a $18.00 target price on shares of Coya Therapeutics in a research note on Monday, November 11th.

Insiders Place Their Bets

In other Coya Therapeutics news, CEO Arun Swaminathan bought 5,000 shares of Coya Therapeutics stock in a transaction that occurred on Monday, November 11th. The stock was acquired at an average cost of $7.34 per share, for a total transaction of $36,700.00. Following the completion of the transaction, the chief executive officer now directly owns 5,000 shares in the company, valued at $36,700. This represents a ∞ increase in their ownership of the stock. The purchase was disclosed in a legal filing with the SEC, which is available through this link. Insiders acquired 9,510 shares of company stock worth $69,615 over the last quarter. 9.80% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On Coya Therapeutics

Several institutional investors have recently added to or reduced their stakes in COYA. Renaissance Technologies LLC purchased a new stake in shares of Coya Therapeutics during the second quarter worth about $101,000. GHP Investment Advisors Inc. purchased a new position in shares of Coya Therapeutics during the third quarter valued at approximately $169,000. Finally, Geode Capital Management LLC raised its holdings in shares of Coya Therapeutics by 3.3% during the third quarter. Geode Capital Management LLC now owns 142,309 shares of the company’s stock valued at $918,000 after acquiring an additional 4,485 shares in the last quarter. Hedge funds and other institutional investors own 39.75% of the company’s stock.

Coya Therapeutics Stock Down 3.9 %

Shares of Coya Therapeutics stock traded down $0.22 during trading on Monday, reaching $5.38. The company’s stock had a trading volume of 63,988 shares, compared to its average volume of 51,707. The company has a market cap of $89.90 million, a price-to-earnings ratio of -8.28 and a beta of 0.46. The firm’s 50-day moving average is $6.02 and its two-hundred day moving average is $6.49. Coya Therapeutics has a 52-week low of $4.75 and a 52-week high of $10.69.

Coya Therapeutics (NASDAQ:COYA) last issued its earnings results on Wednesday, November 6th. The company reported ($0.26) earnings per share for the quarter, beating the consensus estimate of ($0.41) by $0.15. On average, equities research analysts anticipate that Coya Therapeutics will post -1.15 EPS for the current year.

About Coya Therapeutics

Coya Therapeutics, Inc, a clinical-stage biotechnology company, engages in the development of proprietary medicinal products to modulate the function of regulatory T cells (Tregs). The company's product candidate pipeline is based on therapeutic modalities, such as Treg-enhancing biologics, Treg-derived exosomes, and autologous Treg cell therapy.